Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years old * Patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus Exclusion Criteria: * Has received investigational therapy within 60 days prior to study entry * Has received treatment with anti-VEGF agents (intraocular or systemic) within 45 days of study entry * Concurrent use of systemic anti-VEGF agents * Full thickness or lamellar keratoplasty within 90 days prior to study entry * Ocular surface reconstruction within 90 days prior to study entry * Other ocular surgeries within 90 days prior to study entry * Corneal or ocular surface infection within 90 days prior to study entry * Ocular or periocular malignancy * Contact lens (excluding bandage contact lens) within 30 days prior to study entry * Persistent epithelial defect (\>1mm2 and ≥14 days duration) within 30 days prior to study entry * Systemic, intravitreal, or periocular steroids within 30 days prior to study entry * Change in dose/frequency of topical steroids and/or NSAIDs within 30 days prior to study entry * Hypertension: systolic BP \> 150 or diastolic BP \> 90 * History of thromboembolic event within 6 months prior to study entry * Current diagnosis of diabetes, Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception (The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch) * Participation in another simultaneous medical investigation or trial.